Video

Rapid Readouts: Postoperative Chemotherapy Use and Outcomes from ADAURA

Roy S. Herbst, MD, PhD, presents slides from the IASLC 2020 World Conference on Lung Cancer for postoperative chemotherapy use and outcomes from the phase 3 ADAURA trial of osimertinib as adjuvant therapy in patients with resected EGFR mutated NSCLC.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Roy S. Herbst, MD, PhD, presents slides from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC) for postoperative chemotherapy use and outcomes from ADAURA (NCT02511106). The phase 3 trial is investigating osimertinib as adjuvant therapy in patients with resected EGFR-mutated non–small cell lung cancer (NSCLC).

    Roy S. Herbst, MD, PhD, discusses data from the following presentation:

    • Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC.(Wu YL, WCLC 2020, abstract OA06.04)
      • In ADAURA, adjuvant chemotherapy use prior to randomization was balanced across treatment arms and in line with uptake observed in previous studies and clinical practice.

      • Younger age (<70 years) and higher disease stage were associated with increased chemotherapy use, compared with older age (≥70 years) and lower disease stage.

      • Investigators observed a clinically meaningful disease-free survival (DFS) benefit with osimertinib in patients with and without adjuvant chemotherapy (DFS HR, 0.16 and 0.23, respectively), regardless of disease stage.

      • Higher disease recurrence rates were observed among patients in the placebo arm who received adjuvant chemotherapy compared with those who did not. The rates were likely driven by the large proportion of patients with stage II/IIIA disease, as disease stage is a prognostic factor for clinical outcome.

      • Investigators observed a DFS benefit with osimertinib versus placebo in patients whether they had received prior chemotherapy or not. This suggests that adjuvant osimertinib will provide a highly effective treatment for patients with stage IB/II/IIIA EGFR-mutated NSCLC after resection, with or without adjuvant chemotherapy as indicated.